Clinical Trials Logo

Clinical Trial Summary

To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.


Clinical Trial Description

To determine:

- Duration of response

- Progression free survival

- Proportion of responders 2 years after discontinuation of inecalcitol

- Duration of response after discontinuation of inecalcitol and imatinib

- Bone remodelling effect

- Safety of inecalcitol in combination with imatinib

- Quality of Life ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02949570
Study type Interventional
Source Hybrigenics Corporation
Contact Jean-Francois Dufour-Lamartinie, MD
Phone +33-158103805
Email jfdufour@hybrigenics.com
Status Recruiting
Phase Phase 2
Start date February 2014
Completion date April 2018

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06409936 - PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Phase 2
Recruiting NCT05353205 - A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Phase 4
Not yet recruiting NCT06121765 - Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI
Not yet recruiting NCT06423911 - A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML Phase 3
Recruiting NCT03459534 - A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs Phase 3
Completed NCT03885830 - Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
Completed NCT04883125 - Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment Phase 2
Not yet recruiting NCT05367765 - A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Phase 4
Recruiting NCT05367700 - A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. Phase 1